SomantiX BV is rated 3 out of 5 in the category biotechnology. Read and write reviews about SomantiX BV. SomantiX B.V. is a Dutch biotech company focusing on the identification and development of new angiogenesis inhibitors for the treatment of solid cancers through targeting of tumor blood vessels. Somantix’ screening platform in combination with the binder generation technologies allows validation of new therapeutic targets and development of new cancer medicines.
Address
Padualaan 8 Kruyt Gebouw rm O.807
Company size
1-10 employees
Headquarters
Utrecht, Utrecht